INFLAMMATIX PIPELINE

Groundbreaking tests to address unmet needs

Inflammatix host response diagnostics are powered by ‘reading’ the immune system. Our immune system has developed targeted responses to different types of infections and other diseases over millions of years of evolution.

We are harnessing the ability to interpret the immune response to develop tests aimed to help physicians make confident and timely clinical decisions.

Our products are in development, are not for sale, and do not have marketing approval or clearance from regulatory authorities in any jurisdiction.

TriVerity

Acute Infection and Sepsis Test

Shooting for the holy grail: Identify the presence, type and severity of an acute infection.

The test is being developed for emergency rooms, urgent care clinics and inpatient use to diagnose (or rule out) acute infection and sepsis in multiple clinical scenarios:

  • First presentation in the ED or urgent care clinic
  • Identifying infections in traumatic injuries
  • ICU patient monitoring

Product in development, is not for sale, and does not have marketing approval or clearance from regulatory authorities in any jurisdiction.

BacVerity Acute Infection Test characteristics
TriVerity Acute Infection and Sepsis Test decision tree
BacVerity

Acute Infection Test

Soon, we’ll answer your simple question:
Is my infection bacterial or viral?

Ideal for outpatient clinics and urgent care centers. Safely and confidently avoid prescribing antibiotics on negative results (development work suggests the BacVerity test can achieve a greater than 95% negative predictive value for bacterial infection) [1]

Product in development, is not for sale, and does not have marketing approval or clearance from regulatory authorities in any jurisdiction.

BacVerity Acute Infection Test characteristics
BacVerity Acute Infection Test decision tree
Endotypes

Therapy Response Prediction

Unlocking personalized therapies in sepsis and critical illness

Sepsis is defined as a ‘life-threatening dysregulated host response to infection’, and for years, clinical trials have tried and failed to find immunomodulatory therapies for sepsis to bring homeostasis to the immune system. In fact, not a single immunomodulatory therapy for sepsis has been successfully brought to market despite 40+ years of trials [1].

A modern understanding of sepsis using new kinds of molecular and clinical data suggests that the sepsis syndrome may actually be composed of several subtypes of patients. Just like how breast cancer is now properly defined as composed of different subtypes (e.g. ER/PR/HER2 status), a sepsis patient may someday be properly defined as suffering from overramped innate immunity, adaptive immune collapse, endothelial dysfunction, etc. And just like different breast cancer survival rates have improved as each subtype finds a specific treatment, so may sepsis outcomes improve when specific therapies are paired with individual subtypes [2].

Inflammatix has been at the forefront of sepsis subtypes (or ‘endotypes’) research in transcriptomics, with a 33-mRNA classifier that has been repeatedly validated [3, 4] in research settings to produce three subgroups with different outcomes. We are actively working to determine which therapies may show a difference of treatment effect among the three subtypes: 1-Inflammapathic, 2-Adaptive, 3-Coagulopathic.

Product in development, is not for sale, and does not have marketing approval or clearance from regulatory authorities in any jurisdiction.

Endotypes therapy response prediction